EVAX — Evaxion A/S
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1828253 ·
Denmark
Last close
$2.78
Market Cap
$25.08M
52W High
$6.92
52W Low
$2.65
ADV30
108,697
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,846,000 | -3,729,000 | 19,380,000 | 14,000,000 | 9,849,000 |
| Mar 2026 | 0 | — | -3,819,000 | -3,629,000 | 23,642,000 | 18,440,000 | 10,435,000 |
| Dec 2025 | 0 | — | -4,052,000 | -5,918,000 | 28,408,000 | 23,234,000 | 11,369,000 |
| Sep 2025 | 7,492,000 | — | 3,023,000 | 4,618,000 | 29,737,000 | 10,572,000 | 13,138,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-133,603,000
Inventory
—
Receivables
$1,858,000
ST Investments
—
EBIT TTM
$-9,858,000
Pretax Income TTM
$-9,599,000
Interest Exp TTM
$-259,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,491,000
EBITDA
$-8,326,000
Free Cash Flow
$-5,487,625
Enterprise Value
$19,209,872
Total Cash
$14,000,000
Total Debt
$7,105,000
Shares Out
9,021,483
Trailing EPS
$-0.50
Book Value
$1.14
ROE
-109.9%
ROA
-26.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,528,000 | -9,234,000 | -7,707,000 | 28,408,000 | 11,369,000 | 17,039,000 | -6,625,000 |
| Dec 2024 | 3,344,000 | -14,732,000 | -10,567,000 | 12,485,000 | 14,137,000 | -1,652,000 | -12,940,000 |
| Dec 2023 | 73,000 | -22,197,000 | -22,125,000 | 12,889,000 | 17,618,000 | -4,729,000 | -17,691,000 |
| Dec 2022 | 0 | -25,264,000 | -23,169,000 | 22,025,000 | 13,722,000 | 8,303,000 | -25,774,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.01
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LONA | LeonaBio, Inc. | $26.00M | $2.76 | — |
| MGX | Metagenomi Therapeutics, Inc. | $23.86M | $0.63 | — |
| PTHS | Pelthos Therapeutics Inc. | $26.89M | $6.84 | — |
| ZIVO | Zivo Bioscience, Inc. | $23.18M | $5.50 | — |
| SAEN | Genenta Science S.p.A. | $27.82M | $0.58 | — |
News headlines (Yahoo Finance, 1h cache)
Evaxion to announce strategy and business update and third quarter 2026 financial results on November 19, 2026
2026-11-18 13:30 · Yahoo
Evaxion announce 2027 financial calendar
2026-11-12 13:00 · Yahoo
Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement
2026-11-09 13:00 · Yahoo
New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
2026-11-06 16:00 · Yahoo
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting
2026-11-04 14:00 · Yahoo
Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
2026-11-03 14:00 · Yahoo
Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution
2026-10-30 08:00 · Yahoo
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
2026-10-23 06:00 · Yahoo
European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading
2026-10-20 15:10 · Yahoo
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading
2026-11-16 16:21 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.